Advertisement

Neurocritical Care

, Volume 30, Issue 2, pp 372–379 | Cite as

Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial

  • Luiz Antonio NasiEmail author
  • Sheila Cristina Ouriques Martins
  • Miguel Gus
  • Gustavo Weiss
  • Andrea Garcia de Almeida
  • Rosane Brondani
  • Letícia Costa Rebello
  • Angélica DalPizzol
  • Flávio Danni Fuchs
  • Maria Júlia Monteiro Valença
  • Letícia F. Wirth
  • Gerson Nunes
  • Craig S. Anderson
Original Article

Abstract

Introduction

There is uncertainty over the optimal level of systolic blood pressure (SBP) in the setting of acute ischemic stroke (AIS). The aim of this study was to determine the efficacy of the early manipulation of SBP in non-thrombolised patients. The key hypothesis under investigation was that clinical outcomes vary across ranges of SBP in AIS.

Methods

218 patients were randomized within 12 h of AIS to maintain the SBP during 24 h within three ranges: Group 1 140–160 mmHg, Group 2 161–180 mmHg or Group 3 181–200 mmHg. Vasoactive drugs and fluids were used to achieve these targets. Good outcome was defined as a modified Rankin score 0–2 at 90-days.

Results

The median SBP in the three groups in 24 h was: 153 mmHg, 163 mmHg, and 178 mmHg, respectively, P < 0.0001. Good clinical outcome did not differ among the different groups (51% vs 52% vs 39%, P = 0.27). Symptomatic intracranial hemorrhage (SICH) was more frequent in the higher SBP range (1% vs 2.7% vs 9.1%, P = 0.048) with similar mortality rates. No patient had acute neurological deterioration related to the SBP reduction in the first 24 h. In our logistic regression analysis, the odds of having good clinical outcome was higher in Group 2 (OR 2.83) after adjusting for important confounders. Regardless of the assigned group, the probability of good outcome was 47% in patients who were manipulated to increase the BP, 42% to decrease and 62% in non-manipulated (P = 0.1). Adverse effects were limited to Group 2 (4%) and Group 3 (7.6%) and were associated with the use of norepinephrine (P = 0.05).

Conclusions

Good outcome in 90 days was not significantly different among the 3 blood pressure ranges. After logistic regression analysis, the odds of having good outcome was greater in Group 2 (SBP 161–180 mmHg). SICH occurred more frequently in Group 3 (181–200 mmHg).

Keywords

Stroke Ischemic stroke Acute stroke Hypertension Blood pressure 

Notes

Acknowledgements

We thank Magda Martins for the continuous support to finish this study.

Authors’ contribution

LAN planned the study, interpreted the data and wrote the first draft of the report. SCOM planned and supervised the study, interpreted the data and wrote the report. MG planned the study, interpreted the data and wrote the report. GW, AGA, RB, LCR, ADP, MJMV, LFW and GN contributed to the report. FDN reviewed and contributed to the report. CSA interpreted the data and wrote the report.

Source of support

This research was supported by Hospital de Clínicas de Porto Alegre and CAPES. The study was designed, conducted, analyzed and interpreted by the investigators independent of sponsors.

Compliance with Ethical Standards

Conflict of interest

C.S.A reports membership of Advisory Boards for Pfizer and The Medicines Company, and receiving travel reimbursement and honorarium from Takeda China and Covidien. The other authors declare no potential conflict of interest.

Ethical Approval

The study was approved by the Ethical Committee of Hospital de Clínicas de Porto Alegre. All patients (or close relative) provided informed consent.

Supplementary material

12028_2018_642_MOESM1_ESM.docx (76 kb)
Supplemental Table 1. Blood pressure manipulation status, drugs and dose according to randomized group (DOCX 76 kb)
12028_2018_642_MOESM2_ESM.png (360 kb)
Supplemental Fig. 1: MAPAS trial design (PNG 360 kb)

References

  1. 1.
    Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33(5):1315–20.CrossRefGoogle Scholar
  2. 2.
    PROGRESS Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.CrossRefGoogle Scholar
  3. 3.
    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee. JAMA. 2014;311(5):507–20.CrossRefGoogle Scholar
  4. 4.
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRefGoogle Scholar
  5. 5.
    Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefGoogle Scholar
  6. 6.
    Tyrrell P, Swain S, Rudd A, Acute S. NICE guideline on acute stroke and TIA: commentary. Heart. 2009;95(10):843–5.CrossRefGoogle Scholar
  7. 7.
    Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009;8(1):48–56.CrossRefGoogle Scholar
  8. 8.
    Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377(9767):741–50.CrossRefGoogle Scholar
  9. 9.
    Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. Nejm. 2013;368(25):2355–65.CrossRefGoogle Scholar
  10. 10.
    He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311(5):479–89.CrossRefGoogle Scholar
  11. 11.
    Oliveira-Filho J, Martins SC, Pontes-Neto OM, et al. Guidelines for acute ischemic stroke treatment: part I. Arq Neuropsiquiatr. 2012;70(8):621–9.CrossRefGoogle Scholar
  12. 12.
    Nasi LA, Ferreira-Da-Silva AL, Martins SC, et al. Implementation of a dedicated cardiovascular and stroke unit in a crowded emergency department of a tertiary public hospital in Brazil: effect on mortality rates. Acad Emerg Med. 2014;21(1):40–6.CrossRefGoogle Scholar
  13. 13.
    Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Lancet. 2000;355(9216):1670–4.CrossRefGoogle Scholar
  14. 14.
    Adams HP, Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.CrossRefGoogle Scholar
  15. 15.
    Baggio JA, Santos-Pontelli TE, Cougo-Pinto PT, et al. Validation of a structured interview for telephone assessment of the modified Rankin Scale in Brazilian stroke patients. Cerebrovasc Dis. 2014;38(4):297–301.CrossRefGoogle Scholar
  16. 16.
    van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–7.CrossRefGoogle Scholar
  17. 17.
    Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.CrossRefGoogle Scholar
  18. 18.
    Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.CrossRefGoogle Scholar
  19. 19.
    Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (“BEST” trial): an evaluation. BMJ. 1988;296(6624):737–41.CrossRefGoogle Scholar
  20. 20.
    Bravata DM, Ho SY, Brass LM, Concato J, Scinto J, Meehan TP. Long-term mortality in cerebrovascular disease. Stroke. 2003;34(3):699–704.CrossRefGoogle Scholar
  21. 21.
    Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke. 2000;31(6):1250–5.CrossRefGoogle Scholar
  22. 22.
    Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2014;10:CD000039.Google Scholar
  23. 23.
    Saver JL. Time is brain—quantified. Stroke. 2006;37:263–6.CrossRefGoogle Scholar
  24. 24.
    Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke. 2009;40(6):2251–6.CrossRefGoogle Scholar
  25. 25.
    Meyer JS, Shimazu K, Fukuuchi Y, Ouchi T, Okamoto S, Koto A. Impaired neurogenic cerebrovascular control and dysautoregulation after stroke. Stroke. 1973;4(2):169–86.CrossRefGoogle Scholar
  26. 26.
    Powers WJ, Videen TO, Diringer MN, Aiyagari V, Zazulia AR. Autoregulation after ischaemic stroke. J Hypertens. 2009;27(11):2218–22.CrossRefGoogle Scholar
  27. 27.
    Hillis AE, Ulatowski JA, Barker PB, Torbey M, Ziai W, Beauchamp NJ, Oh S, Wityk RJ. A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovasc Dis. 2003;16:236–46.CrossRefGoogle Scholar
  28. 28.
    Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, Buonanno FS. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology. 2001;56(1210):1213.Google Scholar
  29. 29.
    Jusufovic M, Sandset EC, Bath PM, Karlson BW, Berge E. Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. Int J Stroke. 2015;10(3):354–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society 2018

Authors and Affiliations

  • Luiz Antonio Nasi
    • 1
    Email author
  • Sheila Cristina Ouriques Martins
    • 1
    • 2
  • Miguel Gus
    • 3
  • Gustavo Weiss
    • 1
    • 2
  • Andrea Garcia de Almeida
    • 1
    • 2
  • Rosane Brondani
    • 1
    • 2
  • Letícia Costa Rebello
    • 1
    • 2
  • Angélica DalPizzol
    • 1
    • 2
  • Flávio Danni Fuchs
    • 3
  • Maria Júlia Monteiro Valença
    • 1
    • 2
  • Letícia F. Wirth
    • 1
  • Gerson Nunes
    • 1
  • Craig S. Anderson
    • 4
  1. 1.Vascular Unit, Emergency Department, Hospital de Clínicas de Porto AlegreUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  2. 2.Stroke Division, Neurology Service, Hospital de Clínicas de Porto AlegreUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  3. 3.Hypertension Group, Cardiology Service, Hospital de Clínicas de Porto AlegreUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  4. 4.The George Institute for Global Health, Royal Prince Alfred HospitalUniversity of New South WalesSydneyAustralia

Personalised recommendations